Skip to main content
Evidence Snapshot

Hepatitis C virus

CHEMBL379 ORGANISM Hepacivirus hominis
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T02:42:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL379
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatitis C virus as ChEMBL target CHEMBL379. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatitis C virus
ORGANISM · Hepacivirus hominis
As of 2026-09-14
ChEMBL target ID
CHEMBL379
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Hepatitis C virus matters

As of 2026-09-14

Hepatitis C virus is reviewed as Hepatitis C virus; the current evidence base includes 51 approved drugs, 12165 compounds, and 3162 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 51 approved drugs, 12165 compounds, and 3162 assays for this target. The dominant activity type is EC50. CHEMBL2023898 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL2023898 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
51 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Hepatitis C virus matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

12165
Total Compounds
3162
Total Assays
51
Approved Drugs
IC50: 2739.0, KI: 116.0, EC50: 15265.0, KD: 27.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2023898
 11.0 EC50 Approved
No preferred name
CHEMBL2036969
 11.0 EC50 —
No preferred name
CHEMBL2036977
 11.0 EC50 —
No preferred name
CHEMBL3120448
 11.0 EC50 —
No preferred name
CHEMBL3121843
 11.0 EC50 —

Approved Drugs

Structure Compound First Approval
REMDESIVIR
CHEMBL4065616
 2020
GLECAPREVIR
CHEMBL3545363
 2017
GRAZOPREVIR ANHYDROUS
CHEMBL2063090
 2016
ELBASVIR
CHEMBL3039514
 2016
BELINOSTAT
CHEMBL408513
 2014
DACLATASVIR
CHEMBL2023898
 2014
ASUNAPREVIR
CHEMBL2105735
 2014
LEDIPASVIR
CHEMBL2374220
 2014
OMBITASVIR
CHEMBL3127326
 2014
PARITAPREVIR
CHEMBL3391662
 2014
SOFOSBUVIR
CHEMBL1259059
 2013
SIMEPREVIR
CHEMBL501849
 2013
BOCEPREVIR
CHEMBL218394
 2011
TELAPREVIR
CHEMBL231813
 2011
VORINOSTAT
CHEMBL98
 2006
DASATINIB
CHEMBL5416410
 2006
ERLOTINIB
CHEMBL553
 2004
NITAZOXANIDE
CHEMBL1401
 2002
IMIQUIMOD
CHEMBL1282
 1997
GEMCITABINE
CHEMBL888
 1996
RIBAVIRIN
CHEMBL1643
 1985
CYCLOSPORINE
CHEMBL160
 1983
NICLOSAMIDE
CHEMBL1448
 1982
CYTARABINE
CHEMBL803
 1969
HYDROXYZINE
CHEMBL896
 1956
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T02:42:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL379